The massive registered share count (173% of outstanding) creates severe overhang risk, though much is tied up by 4.99%-9.99% beneficial ownership blockers on the warrants. Watch for 424B prospectus supplements signaling actual sales by large holders (Commodore Capital, RA Capital, TCG Crossover), any reduction in ownership caps via 61-day notice would accelerate selling. The $85M PIPE proceeds should extend runway but with Q1 2026 cash of only $35M (after Q2 2026 $34.5M revenue, largely non-cash), capital needs remain acute.
Drugs in focus
AGEN drug pipeline →botensilimab
◆ Mixed Named in this S-3- Impact
- Phase
- Phase 3
- Time to market
- At least 3-5 years if Phase 3 BATTMAN succeeds; accelerated approval pathway was denied by FDA
- Next catalyst
- None dated
What to watchAgenus just announced a heavily dilutive ~$85M PIPE at $3.69/share to fund the Phase 3 BATTMAN trial, the stock is likely to trade under pressure from the overhang. Near-term upside depends on Phase 2 data catalysts (ASCO/ESMO presentations) and potential partnership deals, not regulatory approvals. The ~14.4% short interest adds squeeze risk on positive data surprises, but the fundamental path to commercialization is years away.
How the stock moved after the report
BEARISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Aug 10 $7.00entry
- T+1 · 3mo ago −2.43%α −2.11% · $6.83
- T+5 · 3mo ago +2.14%α +2.19% · $7.15
- T+20 · 2mo ago +10.87%α +11.78% · $7.76
- T+60 · 14d ago −3.43%α −1.53% · $6.76
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Agenus filed a resale registration statement on Form S-3 to register up to 77,976,718 shares of common stock held by selling securityholders from its July 2026 $85M private placement. The filing is a contractual obligation under the Registration Rights Agreement and does not represent a new primary offering, Agenus receives no proceeds from the resale but could receive up to $255M if warrants are exercised for cash. With a $335M market cap, the registered shares represent over 170% of current outstanding shares, creating massive near-term overhang risk even though most warrants are subject to beneficial ownership limitations.
Key Facts
- Registers 77,976,718 shares for resale by selling securityholders, including 1,626,015 issued shares, 21,409,212 pre-funded warrant shares, and 54,941,491 purchase warrant shares
- Registered under Registration Rights Agreement from July 13, 2026 $85M private placement (closed July 15, 2026)
- Agenus receives no proceeds from resale; would receive cash only if warrants exercised, Series A ($4.02 strike) and Series B ($5.03 strike) warrants could yield up to $255M if fully exercised
- Current shares outstanding: 45,009,670 as of July 31, 2026, registered shares equal ~173% of outstanding
- Stock closed at $7.49 on August 6, 2026; Series A and B warrants are in-the-money by $3.47 and $2.46 respectively
- KPMG audit report included a going-concern explanatory paragraph for FY2025 financials
Financial Impact
Max potential warrant exercise proceeds of $255M; registration covers $607.8M in market value of shares at $7.795 reference price
Risk Factors
- Massive potential dilution, registered shares equal ~173% of current outstanding, even with most warrants subject to beneficial ownership caps
- Selling pressure from institutional holders (Commodore Capital, RA Capital, Invus, Ligand, TCG Crossover) who obtained shares at a combined $3.69/unit, now 103% above cost at $7.49
- Going concern risk highlighted by KPMG; pre-revenue clinical-stage company with cash burn and uncertain Phase 3 trial outcomes
- BATTMAN trial terminated due to funding prioritization, narrowing pipeline to botensilimab/balstilimab ROBBIN trial
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| S-3 Filing (Primary) | 0001193125-26-340213 |
| Document: d120245dexfilingfees.htm | 0001193125-26-340213 |
| Document: d120245dex51.htm | 0001193125-26-340213 |
| Document: d120245dex232.htm | 0001193125-26-340213 |
| Document: 0001193125-26-340213-index-headers.html | 0001193125-26-340213 |
| Document: 0001193125-26-340213-index.html | 0001193125-26-340213 |
| Document: 0001193125-26-340213.txt | 0001193125-26-340213 |
Track record
12 reports on AGEN
2 of 4 bullish or bearish reports moved the stock their way by T+60. Best: +138.65% at T+60 after the May 11, 2026 report. 3 of 4 went positive at some point.
Filters
- Nov 16, 2026today SC 13G Neutral 4/10 Entry price pending
- Nov 13, 20263d ago SC 13G Neutral 3/10 Entry $6.97 Now $6.29 −9.76% settles Feb 12
- Nov 5, 202611d ago 8-K Neutral 4/10 Entry $6.44 Now $6.29 −2.33% settles Feb 3
- Aug 12, 202613w ago 8-K Neutral 2/10 Entry $7.00 to $6.90 Now $6.29 −10.14% ▼ −1.43% +3.81% vs SPY
- Aug 12, 202613w ago Institutional Cluster Mixed 4/10 Entry $6.90 to $6.97 Now $6.29 −8.84% ▲ +1.01% +5.89% vs SPY
- Aug 7, 202614w ago S-3 Bearish 7/10 Viewing Entry $7.00 to $6.76 Now $6.29 +10.14% ▲ +3.43% +1.53% vs SPY
- Aug 6, 202614w ago 8-K Neutral 5/10 Entry $7.49 to $6.84 Now $6.29 −16.02% ▼ −8.68% −7.01% vs SPY
- Jul 17, 202617w ago S-3 Bearish 5/10 Entry $4.97 to $6.95 Now $6.29 −26.56% ▼ −39.84% −35.00% vs SPY
- Jul 13, 202618w ago 8-K Bearish 6/10 Entry $6.12 to $7.49 Now $6.29 −2.78% ▼ −22.39% −18.39% vs SPY
- May 13, 202626w ago DEFA14A Neutral 4/10 Entry $3.47 to $6.96 Now $6.29 +81.27% ▲ +100.58% +96.14% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers